Atlas Trials

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Clinical trial NCT03695341 · COMPLETED

Trial details

NCT number
NCT03695341
Sponsor
Fudan University
Status
COMPLETED
Study type
OBSERVATIONAL
Breast Cancer
Start date
2018-05-14
Primary completion
2019-03-10
Enrollment
130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.